Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 183

Results For "standard"

1851 News Found

Morepen to start Sputnik V Vaccine commercial production in 4-6 weeks
News | July 28, 2021

Morepen to start Sputnik V Vaccine commercial production in 4-6 weeks

The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval


Pharma majors collaborate for clinical trial of Molnupiravir for COVID-19
News | June 30, 2021

Pharma majors collaborate for clinical trial of Molnupiravir for COVID-19

The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India


Dr. Reddy's announces commercial launch of 2DG
News | June 29, 2021

Dr. Reddy's announces commercial launch of 2DG

2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's


Lonza to expand API manufacturing facility in Nansha, China
News | June 28, 2021

Lonza to expand API manufacturing facility in Nansha, China

The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022


Honeywell launches solutions to prevent counterfeit pharma products
News | June 23, 2021

Honeywell launches solutions to prevent counterfeit pharma products

The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use


Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
News | June 14, 2021

Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years

The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination


Lupin receives warning letter from U.S. FDA
News | June 14, 2021

Lupin receives warning letter from U.S. FDA

The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility


'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.
Interviews | June 10, 2021

'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.

In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:


Haffkine Biopharma to produce 22.8 Cr doses of Covaxin
News | June 03, 2021

Haffkine Biopharma to produce 22.8 Cr doses of Covaxin

For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra


Zydus new initiative to safeguard patients against counterfeit drugs
News | May 29, 2021

Zydus new initiative to safeguard patients against counterfeit drugs

The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website